Source: Eur Respir J 2016; 48: 1514-1516
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Peter M. Hickey, Alfred A.R. Thompson, Athanasios Charalampopoulos, Charles A. Elliot, Neil Hamilton, David G. Kiely, Allan Lawrie, Ian Sabroe and Robin Condliffe. Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. Eur Respir J 2016; 48: 1514-1516

Member's Comments

No comment yet.

Related content which might interest you: Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Comparison of clinical characteristics in patients with pulmonary arterial hypertension and inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008 Predictors of physical activity in pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension Year: 2019 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017 Chronic thromboembolic pulmonary hypertension: role of medical therapy Source: Eur Respir J 2013; 41: 985-990 Year: 2013 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study Source: Eur Respir J 2010; 36: 792-799 Year: 2010 Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2009; 19: 64-67 Year: 2010 Arterial stiffness in patients with chronic obstructive pulmonary disease combined with arterial hypertension Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020 Medical treatment in persistent pulmonary hypertension after pulmonary thrombendarterectomy in patients with chronic thrombembolic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 364s Year: 2006 First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension Source: Eur Respir J, 51 (3) 1701694; 10.1183/13993003.01694-2017 Year: 2018